Abstract 18P
Background
Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2-) negative early breast cancers (eBCs) represent a significant health concern in the Indian population. Among premenopausal women with HR+ eBC, adjuvant ovarian function suppression (OFS) is considered as an integral component of treatment; however, its optimal utilization remains a subject of ongoing debate.
Methods
In response to identified gaps in clinical practice, a comprehensive questionnaire consisting of 28 statements was developed. These statements were reviewed and validated by a scientific committee, ensuring their accuracy and relevance to the study's objectives. A panel of 46 Indian experts and 1 global expert in the field of eBC were asked to rate their level of agreement/disagreement with each statement. Consensus was defined as achieving a ≥ 80% majority agreement among participants.
Results
Following two rounds of the modified Delphi technique, consensus was achieved on 19 out of 28 statements addressing critical aspects of premenopausal HR+ HER2- eBC management. The expert panel strongly recommends a comprehensive risk stratification approach for premenopausal HR+ HER2- eBC patients. Notably, Patients ≤40 years old are deemed high-risk candidates, recognizing age as an independent risk factor. For patients ≥40 years, a composite assessment incorporating clinicopathological factors (tumor grade, nodal involvement, and Ki67 score) is advised for risk assessment. For high-risk patients, OFS coupled with an Aromatase Inhibitor emerged as a recommended therapeutic strategy. The panel recommends a potential duration of up to 5 years for OFS, provided tolerability is maintained. In patients below 40 years of age, simultaneous initiation of OFS with chemotherapy is advised, while in those aged over 40 years, sequential initiation is deemed acceptable. Among the available LHRH agonists, Triptorelin stands out as the preferred choice, although the panel acknowledges similar efficacy across all options.
Conclusions
The outcomes of this consensus offer valuable guidance, enabling individualized and evidence-based approaches for OFS in Indian patients with HR+ HER2- eBC.
Clinical trial identification
Editorial acknowledgement
BioQuest Solutions Pvt Ltd.
Legal entity responsible for the study
Dr. Reddy's Laboratories.
Funding
Dr. Reddy's Laboratories.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
383P - Pre-treatment body mass index and neutrophil lymphocyte ratio predict 3-years progression free survival in locally advanced stage nasopharyngeal carcinoma
Presenter: Ni Putu Pusvita Dewi
Session: Poster Display
Resources:
Abstract
384P - Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan
Presenter: Wei-Chen Lu
Session: Poster Display
Resources:
Abstract
385P - The prognostic factors of induction chemotherapy followed by concurrent chemoradiotherapy in patients with HPV associated with oropharyngeal cancer
Presenter: Hyun Jin Bang
Session: Poster Display
Resources:
Abstract
386P - FOLR1 stabilized beta-catenin promotes laryngeal carcinoma progression through EGFR signal
Presenter: Huawei Tuo
Session: Poster Display
Resources:
Abstract
387P - A comprehensive analysis of the oral health status, tobacco use, and cancer prevalence among the tribal communities in India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
388P - Clinicopathological correlation of P53 expression in oral cancers
Presenter: Venkata Madhavi Bellala
Session: Poster Display
Resources:
Abstract
389P - Lack of cross-resistance to erlotinib in human head and neck cancer cells with acquired resistance to cetuximab
Presenter: James A. Bonner
Session: Poster Display
Resources:
Abstract
390P - Epidemiological aspects of the development of oral cancer in the Republic of Uzbekistan
Presenter: Akhrorbek Yusupbekov
Session: Poster Display
Resources:
Abstract
391P - Lip cancer: Racial disparities, treatment modalities and long-term survival outcome in young and adults versus older age patients
Presenter: FathAlrahman Ibrahim
Session: Poster Display
Resources:
Abstract
392TiP - A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy
Presenter: Juyi Wen
Session: Poster Display
Resources:
Abstract